# Metformin and a GLP-1 Together: The Risk Is Not the One People Expect

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-09-11 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/metformin-and-a-glp1-together

> The diabetes trials behind these drugs were largely run on people already taking metformin. Stomach side effects did not stack in the largest analysis, and low blood sugar comes from other drugs. The real overlap is dehydration.

## Key points

- SURPASS-2 randomized 1,879 adults already on metformin alone; in a 2024 pooled analysis, 76% of 16,996 participants were on metformin when the GLP-1 started.
- Being on metformin did not increase stomach side effects, their severity or stopping the GLP-1 in that analysis; starting both at once was not studied.
- The labels name insulin and sulfonylureas as the low-blood-sugar risk: 3.6% on liraglutide plus metformin vs 27.4% once a sulfonylurea was added.
- GLP-1 labels warn of kidney injury after vomiting or diarrhea, and kidney impairment is the first risk factor metformin's label names for lactic acidosis. Case reports only; no rate exists.

Yes, metformin and a GLP-1 are taken together routinely, and most of the diabetes trials behind these drugs were run on people already taking metformin. The two worries people bring to the question, twice the stomach trouble and low blood sugar, are not where the evidence points. The place these two drugs meet is dehydration, and that is worth knowing about before a bad week of vomiting, not during it.

> **About this article.** Written from the current FDA labels on DailyMed, the trials behind them and the 2026 American Diabetes Association Standards of Care. Nothing here is a reason to change a dose. If you take both drugs, the person who prescribes them is the one to ask about anything below.

## The trials were run on top of metformin

This combination is not an edge case the trials missed. It is largely what they tested. SURPASS-2, the head-to-head that put tirzepatide against semaglutide, enrolled 1,879 people with type 2 diabetes who were on stable doses of metformin alone and added one drug or the other.[4] Ozempic’s label lists it as studied with metformin, and in one of its core trials 94% of participants were on metformin.[5] Across four large semaglutide and liraglutide trials pooled in a 2024 analysis, 12,928 of 16,996 participants (76%) were taking metformin when the GLP-1 started.[1]

The 2026 ADA Standards describe metformin as the drug that “historically has been the first-line treatment for type 2 diabetes”, and the word “historically” matters. They now recommend considering combination therapy from the start (recommendation 9.6, grade A), and for people with heart disease or high cardiovascular risk they recommend a GLP-1 or SGLT2 drug with proven benefit “independent of A1C, with or without metformin use”.[13] What happens when a GLP-1 and an SGLT2 drug are taken together is covered in [an SGLT2 and a GLP-1 together](https://glpwatchdog.org/research/sglt2-and-a-glp1-together).

## Stomach side effects: the best evidence says they do not stack

Metformin earns its reputation. In the trial on its own label, diarrhea hit 53% of people taking it against 12% on placebo, and nausea or vomiting 26% against 8%.[7] Put that beside a GLP-1 and the obvious guess is that the two add up. The largest analysis of the question found the opposite.

A 2024 analysis pooled four trials (LEADER, STEP 2, SUSTAIN-6 and PIONEER 6) and compared people who were already on metformin when their GLP-1 began with people who were not. Metformin did not raise the share who developed stomach side effects, did not make them more severe, and did not make people more likely to stop the drug. If anything the direction ran the other way: within each arm, a numerically higher share of the people *not* on metformin had stomach side effects and quit.[1] A UK audit of 4,442 people starting liraglutide in ordinary practice pointed the same way. There, not being on metformin was associated with worse stomach side effects.[3]

> Two limits travel with that finding. First, it compares people **already settled on** metformin; the authors write that they “did not evaluate simultaneous initiation of metformin and GLP-1RA”, and we found no study of starting both at the same time. Second, the authors point out that people who could not tolerate metformin may simply be more prone to stomach side effects, which would make the group not taking it look worse for reasons unrelated to the GLP-1.[1] And one earlier analysis of 32 trials disagreed, finding background metformin linked to more nausea and vomiting.[2]

If you have been on metformin for months and are adding a GLP-1, the best evidence says the stomach side effects are the GLP-1’s own and follow its usual course. They concentrate in the weeks after each dose increase, as covered in [how long GLP-1 side effects last](https://glpwatchdog.org/research/how-long-do-glp1-side-effects-last). If the diarrhea itself is the problem, [what actually helps with GLP-1 diarrhea](https://glpwatchdog.org/research/glp1-diarrhea-what-helps) goes through what has and has not been tested. If you are about to start both at once, we found no study that measured what that does, and that is a conversation to have before the first dose rather than after.

## Low blood sugar comes from the other drugs

The labels say where the low-blood-sugar risk comes from by naming it. The Ozempic and Mounjaro warnings are worded almost identically: taking the drug alongside insulin, or alongside a drug that makes the pancreas release insulin such as a sulfonylurea, raises the chance of low blood sugar, severe episodes included. Metformin is not named.[5][4] Metformin’s own label names the same two classes.[7]

The Victoza label is the one place the numbers sit side by side. Low blood sugar that people treated themselves was reported by 3.6% on liraglutide plus metformin and 2.5% on placebo plus metformin. Add glimepiride, a sulfonylurea, to the same combination and it rose to 27.4%.[6] Semaglutide’s label also lists metformin among the drugs tested for a pharmacokinetic interaction and found none that needed a dose change.[5] Who is at risk of a low on these drugs is worked through in [GLP-1 drugs and low blood sugar](https://glpwatchdog.org/research/glp1-low-blood-sugar-risk).

## Where the two drugs actually meet: dehydration

Every GLP-1 label carries a warning about acute kidney injury, and it names the route. On Ozempic’s, most of the reported cases were in people who had become dehydrated through nausea, vomiting or diarrhea.[5] That warning, and what it means for the kidneys, is covered in [GLP-1 drugs and your kidneys](https://glpwatchdog.org/research/glp1-and-your-kidneys).

Metformin’s rare serious hazard, lactic acidosis, runs through the same organ. Its boxed warning lists the risk factors, and renal impairment comes first; the label adds that post-marketing cases “primarily occurred in patients with significant renal impairment”. The patient information goes one step further and says what can bring that on: getting dehydrated, which “can happen if you are sick with a fever, vomiting, or diarrhea.”[7]

Put the two warnings together and the path is short: a GLP-1 causes vomiting, the vomiting causes dehydration, the dehydration injures the kidneys, and impaired kidneys are the first risk factor metformin’s label names for lactic acidosis. The published cases follow that path. A 70-year-old on a stable, maximally tolerated dose of metformin started liraglutide, developed unrelenting vomiting in the third week, and arrived at hospital in severe lactic acidosis.[8] A 2026 report describes dehydration after starting semaglutide ending in kidney failure and life-threatening lactic acidosis.[9] A 2026 series describes four critically ill patients on high-dose metformin who needed renal replacement therapy after a GLP-1 was started or its dose raised, or during a stomach illness while on one.[10]

> What those cases do not give you is a rate. They are case reports (a handful of people, published because they were unusual), and no cohort or pharmacovigilance study has measured how often this happens to people taking both drugs. The reason to know about it is that the path is predictable, and the moment it matters is a specific one: a day or more of not keeping fluids down, especially early on or after a dose increase. That is the day to call the prescriber, not the day to push through.

## Does metformin add weight loss on top of a GLP-1?

Outside of polycystic ovary syndrome, we found no randomized trial that tested it. The trials that exist are small, short and in PCOS. In one, 40 women who had [lost little weight on metformin](https://glpwatchdog.org/research/metformin-for-weight-loss) were randomized for 12 weeks, and 36 completed it: the combination of liraglutide 1.2 mg and metformin lost 6.5 kg on average, against 3.8 kg on liraglutide alone and 1.2 kg on metformin alone.[11] But a later trial from the same group put that low-dose combination against full-dose liraglutide 3 mg on its own, and the single drug won: 6.3 kg against 3.6 kg over 12 weeks, although the combination caused less nausea.[12]

So the finding is narrow. Metformin may add something when the GLP-1 dose is low, in PCOS, over three months. Nobody has shown it adds anything to a full weight-loss dose of semaglutide or tirzepatide. How a GLP-1 compares with metformin as a PCOS treatment in its own right is covered in [GLP-1 drugs for PCOS](https://glpwatchdog.org/research/glp1-for-pcos), and our [semaglutide board for PCOS](https://glpwatchdog.org/best/semaglutide-providers/for-pcos) sets those trial figures beside the sellers we rank. Whether either drug helps people live longer is a separate question, covered in [metformin vs a GLP-1 for longevity](https://glpwatchdog.org/research/metformin-vs-glp1-for-longevity).

## One thing to keep checking on metformin

Long-term metformin can lower vitamin B12. In its trials, about 7% of people with previously normal levels fell below normal, and the label asks for B12 to be measured every two to three years.[7] That is metformin’s effect. We found no good evidence that adding a GLP-1 makes it worse, so the check is the same one it always was.

## Frequently asked questions

### Can you take metformin and Ozempic together?

Yes, and in type 2 diabetes it is a routine pairing. Ozempic's label lists it as studied with metformin, and in one of its core trials 94% of participants were on metformin. Mounjaro's head-to-head trial against semaglutide enrolled only people already taking metformin. Whether it suits you is for the person who prescribes both to decide.

### Does taking metformin with a GLP-1 make the stomach side effects worse?

In the largest analysis, no. Pooling four trials and 16,996 people, being on metformin when a GLP-1 started did not increase stomach side effects, their severity or the chance of stopping. Two limits: it studied people already settled on metformin, not people starting both at once, and one earlier analysis of 32 trials found more nausea and vomiting with background metformin.

### Will metformin and a GLP-1 cause low blood sugar?

The labels do not name metformin as the risk. The GLP-1 labels warn about low blood sugar when the GLP-1 is taken alongside insulin or a sulfonylurea. On the Victoza label, self-treated low blood sugar was 3.6% with liraglutide plus metformin versus 2.5% with placebo plus metformin, rising to 27.4% once a sulfonylurea was added.

### What is the real risk of combining metformin with a GLP-1?

Dehydration. GLP-1 labels warn that kidney injury has occurred mostly in people dehydrated by nausea, vomiting or diarrhea, and metformin's lactic acidosis risk rises when the kidneys are impaired; its patient information names vomiting and diarrhea as causes of dehydration. Published case reports describe this sequence, but how often it happens has never been measured. If you cannot keep fluids down, contact your prescriber.

### Does adding metformin to a GLP-1 help you lose more weight?

It has only been tested in small 12-week trials in women with PCOS. One found liraglutide 1.2 mg plus metformin lost more weight than liraglutide 1.2 mg alone, but another found full-dose liraglutide 3 mg alone beat the combination. No trial has shown metformin adds weight loss to a full weight-loss dose of semaglutide or tirzepatide.

## References

1. Klein KR, Clemmensen KKB, Fong E, et al. Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6. Diabetes Care. 2024. PMID: 38048543. https://pubmed.ncbi.nlm.nih.gov/38048543/
2. Bettge K, Kahle M, Abd El Aziz MS, et al. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Diabetes, Obesity & Metabolism. 2017. PMID: 27860132. https://pubmed.ncbi.nlm.nih.gov/27860132/
3. Thong KY, Gupta PS, Blann AD, et al. The influence of age and metformin treatment status on reported gastrointestinal side effects with liraglutide treatment in type 2 diabetes. Diabetes Research and Clinical Practice. 2015. PMID: 25937541. https://pubmed.ncbi.nlm.nih.gov/25937541/
4. Eli Lilly and Company MOUNJARO (tirzepatide) injection, for subcutaneous use — prescribing information (sections 5.3, 14). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
5. Novo Nordisk OZEMPIC (semaglutide) injection, for subcutaneous use — prescribing information (sections 5.5, 5.6, 12.3, 14). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
6. Novo Nordisk VICTOZA (liraglutide) injection, for subcutaneous use — prescribing information (section 6.1). DailyMed, U.S. National Library of Medicine. 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4
7. Zydus Pharmaceuticals (USA) Inc. METFORMIN HYDROCHLORIDE tablets — prescribing information and patient information (boxed warning, sections 5.1, 5.2, 6.1). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c82a10fa-1e8e-46b6-890a-737de3f34ee1
8. Hooda A, Mehta A, Hannallah F. Metformin-associated lactic acidosis precipitated by liraglutide use: adverse effects of aggressive antihyperglycaemic therapy. BMJ Case Reports. 2018. PMID: 30567126. https://pubmed.ncbi.nlm.nih.gov/30567126/
9. Albany Z, Roe D, Gutteridge D, et al. Two Doses to ICU or When Lactate Equals Glucose: Life-Threatening Lactic Acidosis due to Metformin After Initiation of Semaglutide. Case Reports in Critical Care. 2026. PMID: 42147805. https://pubmed.ncbi.nlm.nih.gov/42147805/
10. Hussain H, Ali M, Lorlowhakarn K, et al. Co-prescription of metformin and glucagon-like peptide-1 receptor agonists and metformin-associated lactic acidosis: A case series. Clinical Nephrology. Case Studies. 2026. PMID: 42164410. https://pubmed.ncbi.nlm.nih.gov/42164410/
11. Jensterle Sever M, Kocjan T, Pfeifer M, et al. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. European Journal of Endocrinology. 2014. PMID: 24362411. https://pubmed.ncbi.nlm.nih.gov/24362411/
12. Jensterle M, Kravos NA, Goričar K, et al. Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. BMC Endocrine Disorders. 2017. PMID: 28143456. https://pubmed.ncbi.nlm.nih.gov/28143456/
13. American Diabetes Association Professional Practice Committee for Diabetes 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026. Diabetes Care. 2026. PMID: 41358900. https://pubmed.ncbi.nlm.nih.gov/41358900/

---

Cite as: GLP Watchdog, Ruth Calder, "Metformin and a GLP-1 Together: The Risk Is Not the One People Expect", published 2026-09-11, updated 2026-10-30. https://glpwatchdog.org/research/metformin-and-a-glp1-together

Canonical HTML page: https://glpwatchdog.org/research/metformin-and-a-glp1-together

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.